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In Alzheimer's disease (AD), amyloid plaques are surrounded by reactive astrocytes with an increased expression of intermediate filaments including glial fibrillary acidic protein (GFAP). Different GFAP isoforms have been identified that are differentially expressed by specific subpopulations of astrocytes and that impose different properties to the intermediate filament network. We studied transcript levels and protein expression patterns of all known GFAP isoforms in human hippocampal AD tissue at different stages of the disease. Ten different transcripts for GFAP isoforms were detected at different abundancies. Transcript levels of most isoforms increased with AD progression. GFAPd-immunopositive astrocytes were observed in subgranular zone, hilus, and stratumelacunosumemoleculare. GFAPd-positive cells also stained for GFAPa. In AD donors, astrocytes near plaques displayed increased staining of both GFAPa and GFAPd. The reading-frameeshifted isoform, GFAP þ1 , staining was confined to a subset of astrocytes with long processes, and their number increased in the course of AD. In conclusion, the various GFAP isoforms show differential transcript levels and are upregulated in a concerted manner in AD. The GFAP þ1 isoform defines a unique subset of astrocytes, with numbers increasing with AD progression.
These data indicate the need for future exploration of underlying mechanisms concerning the functions of GFAPd and GFAP þ1 isoforms in astrocytes and their possible role in AD pathology.
Ó 2014 Elsevier Inc. All rights reserved.
Introduction
Astrocyte processes envelope neuronal synapses and form, together with the pre-and postsynaptic elements, the tripartite synapse. There is ample evidence that astrocytes are actively involved in modulating synaptic transmission (Halassa and Haydon, 2010; Lee et al., 2012; Seth and Koul, 2008) . In response to damage inflicted to the central nervous system, astrocytes can change into a so-called reactive state. This transition termed astrogliosis is characterized by an increase in the expression of their main intermediate filament (IF), glial fibrillary acidic protein (GFAP), by morphological alterations (hypertrophy) and by functional changes (Kato et al., 1998; Pekny and Nilsson, 2005; Simpson et al., 2008; Verkhratsky et al., 2010; Vincent et al., 2010) . Intermediate filaments are dynamic structures that are involved in a range of cellular processes during homeostasis and stress; however, the functional consequences of increased GFAP expression in reactive astrocytes are not understood (Middeldorp and Hol, 2011; Sofroniew and Vinters, 2010) .
Amyloid plaques are a neuropathological hallmark of Alzheimer's disease (AD), and they are surrounded by reactive astrocytes already at an early stage of the disease (Carter et al., 2012; Kamphuis et al., 2012; Sofroniew and Vinters, 2010) . GFAP expression is highly associated with plaque load and, to a lesser extent, W.K. and J.M. contributed equally to this work.
with the number of neurofibrillary tangles (Hanzel et al., 1999; Muramori et al., 1998; Vehmas et al., 2003) . Recently, it has been shown that reactive gliosis limits amyloid deposition (Chakrabarty et al., 2010; Furman et al., 2012) , and that the presence of GFAP plays a crucial role in this (Kraft et al., 2012) . Furthermore, GFAP/ vimentin double knockout mice show a reduced hypertrophy of cell processes and greater sensitivity for spinal cord injury and as well as having a larger infarct volume after ischemia, indicating that GFAP has protective role of GFAP and that a proper IF network is a crucial component of reactive gliosis (Li et al., 2008; Nawashiro et al., 1998 Nawashiro et al., , 2000 Wilhelmsson et al., 2004) . Several functional consequences of a change in GFAP IF network have been reported. GFAP overexpression, GFAP isoform ratios, and mutations in the tail and rod domain all influence IF network structure and reduce the motility of glioma cells in vitro (Elobeid et al., 2000; Kamphuis et al., 2012; Lepekhin et al., 2001; Roelofs et al., 2005; Yoshida et al., 2007) . Astrocytes lacking IFs fail to form a barrier-like structure around amyloid-b (Ab) deposits (Lepekhin et al., 2001; Lu et al., 2011; Wilhelmsson et al., 2004; Xu et al., 1999) . Furthermore, evidence has been presented that the GFAP network is involved in intracellular vesicle motility (Potokar et al., 2007 (Potokar et al., , 2010 , and that the IF network serves as a platform for signal transduction (Pallari and Eriksson, 2006) and translation (Kim and Coulombe, 2010) .
A variety of GFAP isoforms have been described. To date, at least 9 splice variants of GFAP transcripts have been identified in different species (human, mouse, rat) (Kamphuis et al., 2012; Middeldorp and Hol, 2011) . The canonical form, GFAPa, has 9 exons and is specifically expressed in astrocytes. GFAPb has an alternative upstream transcriptional start site in the 5'UTR (Condorelli et al., 1999b; Feinstein et al., 1992; Kamphuis et al., 2012) . GFAPg lacks exon 1 and includes the last 126 bp of intron 1-2 (Zelenika et al., 1995) . Four splice variants, GFAPDEx6, GFAPD164, GFAPD135, and GFAPDEx7, skip sequences in exon 6/7, and were identified in AD tissue, focal lesions assocated with chronic epilepsy, and a specific human astrocyte subtype (Boer et al., 2010; Hol et al., 2003; Kamphuis et al., 2012; Middeldorp et al., 2009b) . These splice variants encode for a frameshifted GFAP protein, termed GFAP þ1 , with a frameshifted carboxyterminus against which we have raised a specific antibody named GFAP þ1 (Hol et al., 2003; Middeldorp et al., 2009b) . In an article by Zelenika et al., a transcript including the last 284 bp of intron 8e9 was reported, which we found to be highly expressed in the mouse brain and which we termed GFAP-zeta (GFAPz) (Kamphuis et al., 2012; Zelenika et al., 1995) . In GFAPd and GFAPk isoforms, exons 8 and 9 are replaced by intron 7e8 sequences (Blechingberg et al., 2007; Kamphuis et al., 2012; Nielsen et al., 2002; Roelofs et al., 2005) . GFAPd is highly expressed in proliferating cells in the subventricular zone and in the subpial layer of the human brain (Roelofs et al., 2005; van den Berge et al., 2010) . The different splice variants result in different GFAP isoforms with variable C-terminal regions. Because the tail domains are important for the assembly of GFAP filaments and for the binding of interacting proteins (Nielsen et al., 2002; Perng et al., 2008) , a differential expression may result in a different GFAP cellular IF network, leading to a different morphology and even an altered function of astrocytes. Recently we published an extensive survey on the gene expression of GFAP isoforms and GFAP protein distribution in the mouse brain and in response to plaque-related gliosis in an AD mouse model (Kamphuis et al., 2012) . The gene expression profile of the GFAPisoforms was shown to remain invariable with age and did not alter as a consequence of plaque-related gliosis. At the protein level, only GFAPa and GFAPd could be localized, with GFAPd present at relatively high levels not only in neurogenic cells in the subventricular and subgranular zones but also in astrocytes located in the subpial region (Kamphuis et al., 2012) .
In previous articles, we reported observations on the differential expression of GFAPd (Roelofs et al., 2005; van den Berge et al., 2010) and GFAP þ1 (Boer et al., 2010; Hol et al., 2003; Middeldorp et al., 2009b) in distinct types of astrocytes in the human brain; however, a systematic description of all human GFAP isoforms in relation to AD pathology has not yet been published. To this end, we investigated the changes in GFAP isoform transcript levels and protein distribution in AD tissue and at different stages of the disease. We focused on the hippocampus, which is one of the brain areas earliest and most severely affected by AD (Braak and Braak, 1991; Gomez-Isla et al., 1997) . We collected tissue from a large number of donors that were classified for amyloid stage (Thal et al., 2000a) and Braak stage of neurofibrillar degeneration (Braak and Braak, 1991) , as indicators for the progression of AD.
Methods

Human post-mortem brain material
Human post-mortem brain material was obtained from the Netherlands Brain Bank (NBB). Snap-frozen (non-fixed and without freeze protection) tissue of the hippocampal area was obtained. For all 75 donors, the medical history was retrieved by the NBB, and an extensive neuropathological assessment was performed by the NBB on multiple brain areas. Next to the staging for amyloid load (Thal et al., 2000a) , all donors were also Braak staged for tau (Braak and Braak, 1991) . The hippocampal area included the dentate gyrus (DG), area CA1-4, and variable parts of subiculum and, occasionally, entorhinal cortex.
Details of the donors, ranked according to their amyloid score (O, A, B, C), are presented in Supplementary Table 1. Donors were sex and age matched as much as possible, but the amyloid O donors of the frozen tissue were significantly younger compared to the amyloid B (p < 0.047) and amyloid C (p < 0.023) donors. The age of the amyloid O group (n ¼ 13) ranged from 51e96 years (mean, 70 years); amyloid A (n ¼ 8) ranged from 64e90 years (mean, 76 years); amyloid B (n ¼ 10) ranged from 64e93 years (mean, 83 years); and amyloid C (n ¼ 34) ranged from 57e96 years (mean, 80 years). In addition, 10 donors were included that did not have an NBB-documented amyloid score, but were scored for tau pathology. The post-mortem delay ranged from 3e11 hours (mean 6 hours) and did not differ between groups. In addition, the pH of the CSF (no significant differences among groups), brain weight (reduced by 15% in amyloid C vs. amyloid O; p < 0.001), and ApoE genotype were provided for most donors.
Cloning GFAP splice variants into pcDNA3
Expression plasmids containing full length isoforms were constructed by modifying the pcDNA3-GFAPa full-length plasmid (Roelofs et al., 2005) . (For details, see Supplementary Material and Methods.)
RNA isolation and real-time quantitative polymerase reaction assays
Cryosections of 10-mm thickness were cut, and 20 sections were collected in a tube kept cold at À20 C. Tissue sections were subsequently thawed and dissolved by adding 1 mL of TRIzol (Life Technologies) at room temperature, followed by thorough vortexing. RNA was isolated from the 400 mL aqueous phase by precipitation at À20 C overnight in 400 mL isopropanol, with the addition of 1 mL of 20 mg/mL glycogen (Roche). The quality of the RNA was determined on a Bioanalyzer (Agilent Technologies) and expressed as RNA Integrity Number (RIN). Total RNA (1 mg) was DNaseI treated and used as a template to generate cDNA following the manufacturer's instructions (Quantitect; Qiagen) using a combination of oligo-dT and random primers for optimal priming. Incubation was for 30 minutes at 42 C. Diluted cDNA served as a template in realtime quantitative polymerase chain reaction (PCR) assays (SYBR Green PCR Master Mix; Applied Biosystems). (For primer sequences, see Supplementary Table 2 ; genes are indicated with the abbreviated formal National Center for Biotechnology Information [NCBI] name.) Expression levels of 13 candidate reference genes (GAPDH, ACTB, PPIA, UBE2D2, EEF1A, RPS27A, AARS, XPNPEP1, RPLP0, IPO, POLR2A, HPRT, RNA18S5) were determined (Durrenberger et al., 2012; Wang et al., 2012) in a larger set of donors. A geNorm analysis on the stability of the transcript levels led us to exclude POLR2A, HPRT, and RNA18S5 from the set of reference genes (Vandesompele et al., 2002) .
Primer specificity and sensitivity was tested on dilution series of cloned GFAP isoforms in pcDNA3 ranging from 1 nge4 fg input. Particular attention was given to potential unwanted crossamplification of GFAPa, the most abundant transcript isoform present in brain tissue. In addition, qPCR products were also run on agarose gels to confirm the anticipated amplicon size (data not shown).
Immunocytochemistry
Sections (10 mm) cut from frozen brain samples were mounted on Superfrost Plus slides (Thermo Scientific), fixed for 10 minutes with freshly prepared 4% paraformaldehyde in phosphatebuffered saline (PBS; 137 mmol/L NaCl, 2.7 mmol/L KCl, 1.8 mmol/L KH 2 PO 4 , and 4 mmol/L Na 2 HPO 4 , pH 7.4), washed, and blocked with 10% normal donkey serum þ 0.04% Triton X-100 in 0.05 mol/L phosphate buffer (PB; pH7.4) for 1 hour. Incubation with the different GFAP-isoformespecific antibodies was carried out overnight at room temperature in 3% normal donkey serum þ 0.04% Triton X-100 in PB. Immunostaining was visualized with 1:1400 diluted Cy3-or AlexaFluor 488econjugated secondary antibodies (Jackson ImmunoResearch Laboratories) incubated for 2 hours in PB and washed in PB. Sections were treated with Sudan Black (0.3% Sudan Black in 70% ethanol) for 7 minutes to quench autofluorescence, and were then washed in 70% ethanol for 50 seconds. After a final wash in PB, sections were cover-slipped in Vectashield with added DAPI as a nuclear dye (Vector Laboratories) and viewed with a Leica DMRE fluorescence microscope. Plaques were localized with thioflavin-S or by antibodies against Ab (6E10-Signet/Covance). Negative controls were included by omitting the primary antibody, but these did not yield staining patterns, and autofluorescence was recognized by a positive signal at all filter settings.
U343 cells and SW-13cl.2 cells, cultured on gelatin-coated coverslips, were rinsed with PBS, and after fixation with 4% formalin in PBS, immunostainings were carried out along the procedure described above for cryosections.
For double-labeling of 2 rabbit primary antibodies (GFAP þ1 in combination with GFAPpan or S100B), the protocol was adapted, such that first primary antibody was applied as before, followed by incubation with Fabeanti-rabbit Cy3 antibody (Jackson Immuno Research, 1:800 in Tris-buffered salineebovine serum albumin [TBS-BSA] ). After rinsing, sections were incubated for at least 5 hours with unlabeled Fabeanti-rabbit fragments (Jackson Immuno Research, 1:150 in TBS-BSA), followed by incubation with the second primary antibody and Fabeanti-rabbit AlexaFluor 488 as before. As a control, 1 of the primary antibodies was omitted to confirm specificity of the detected patterns. -expressing fibers without a clear indication of the associated cell body were left out of the quantification.
For the quantification of amyloid plaques in the hippocampal area, a macro for automated segregation was developed for ImagePro software (MediaCybernetics, Bethesda, MD). In the combined tiled image of the whole tissue section, a mask would be placed over all green fluorescent structures with intensity greater than 3 times the background intensity. The mask was inspected manually to correct for obvious staining artifacts, and the total area of Ab immunoreactivity was automatically calculated. Subsequently, an outline of the whole section was made to calculate the surface area, to correct for differences in section size between donors. The percentage of the total surface area covered by Ab immunoreactivity was calculated.
To determine whether the quantification of the number of Compared to the much larger variation between donors in the different Braak groups using a single section for each donor (average variance over the different Braak groups was 48%), we concluded that measuring 1 section per donor was sufficient.
Western blot
To obtain recombinant protein samples for western blotting, pcDNA3 expression plasmids for GFAPa, GFAPd, GFAPk, GFAPD135, GFAPD164, and GFAPDEx6 were transfected separately into SW13cl.2 cells. Protein was isolated from these cells by homogenization with lysis buffer (0.1 mol/L NaCl, 0.01 mol/L Tris-HCl [pH 7.6], and 1 mmol ethylenediaminetetraacetic acid (EDTA; pH 8.0)) supplemented with a protease inhibitor cocktail (Roche). The samples were dissolved in 2x loading buffer (2x: 100 mmol/L Tris, 4% sodium dodecyl sulfate [SDS] , 20% glycerol, 200 mmol/L ditthiothreitol (DTT), and 0.006% bromophenol blue) and boiled for 5 minutes. Subsequently, the samples were run on a 7.5% SDSepolyacrylamide gel electrophoresis (SDS-PAGE) gel and blotted semi-dry on nitrocellulose. Primary antibodies GFAP þ1 , GFAPpan, and GFAPc-term (see Table S3 for details) were diluted in Supermix (0.05 mol/L Tris, 0.9% NaCl, 0.25% gelatin, and 0.5% Triton X-100, pH 7.4). The next day, the blots were washed with TBS-T (100 mmol/L Tris-HCl [pH 7.4], 150 mmol/L NaCl, with 0.2% Tween-20) and incubated with anti-rabbit IRDye800 or anti-goat IRDye800 (1:5000; Rockland Immunochemicals, Gilbertsville, PA) in Supermix for 1 hour at room temperature. After 3 washes in TBS, bands were visualized with the Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NB).
Antibodies
Antibodies used in this study are listed in Supplementary  Table 3 . Based on the differential sequences in the C-terminal domains of the GFAP isoforms, isoform-specific epitopes were selected. The specificity of the antibodies against human GFAPd and GFAP þ1 has been described previously (Middeldorp et al., 2009b; Roelofs et al., 2005) . Two different polyclonal antibodies against the specific sequences in human GFAPk were raised in rabbits. Basic Local Alignment Search Tool (BLAST; NCBI) analysis did not show significant homologies of the peptide sequences with other proteins. The peptide was either coupled to thyroglobulin or to keyhole limpet hemocyanin (KLH) in a 1:1 ratio using glutaraldehyde, dialyzed against 2% sodium metabisulphite (pH 6.5). After collecting pre-immune serum, rabbits were injected with 2e5 mg of coupled peptide mixed with either Specol or Freund's Complete Adjuvant, followed by 2 or 3 booster immunizations. Both antibodies gave similar results.
Cell culture and transfections
The human adrenal carcinoma cell line SW-13cl.2 (Sarria et al., 1994) and astrocytoma cell line U343 were used for transfection and stainings. SW-13cl.2 cells do not express intermediate filaments and U343 cells express vimentin, nestin, and GFAP, but under normal circumstances no GFAP þ1 isoforms (Middeldorp et al., 2009b) . (For details, please see Supplemental data.)
Ab preparation and MTT assay
Ab1-42 preparations enriched in oligomers and fibrils were obtained as described previously (Chafekar et al., 2007) . In short, Ab1-42 peptide (Anaspec, San Jose, CA) was dissolved in 1,1,1,3,3,3-hexafluoroisopropanol (1 mg/mL; Sigma, St. Louis, MO), resuspended in dimethyl sulfoxide (DMSO) to a concentration of 2.5 mmol/L, and bath sonicated for 10 minutes. Oligomer enrichment was realized by addition of phenol redefree DMEM under continuous vortexing and incubation at 4 C for 24 hours. For fibril enrichment, 10 mmol/L HCl was added under continuous vortexing, followed by incubation at 37 C for 24 hours. Protein concentrations were measured with a Bradford protein assay (Biorad, Hercules, CA), and characterization of the Ab1-42 aggregates was performed by electron microscopy and a thioflavin T assay.
Metabolic activity of cells was assessed by the 3-(4,5-dimthylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described previously (Middeldorp et al., 2009a) . Briefly, U343 cells were incubated with 1 mmol/L oligomeric or fibrillar Ab1-42 for 1 day, 3 days, or 7 days. After that, cells were incubated with MTT (0.25 mg/mL) for 4 hours at 37 C. Next, the formazan crystals generated by the cells as a result of MTT conversion by mitochondrial activity were dissolved in DMSO, and absorbance was measured at 570 nm on a microplate reader (Molecular Devices Corp., Sunnyvale, CA).
Statistical analyses
Data from human hippocampal tissue were non-normally distributed and did not show equality of variances between groups; therefore analyses were performed using non-parametric methods. To describe the central tendency and the spread, data are presented as median and the 25the75th percentile range. The relationship between individual groups (Braak stage, age, and sex) was determined using a KruskaleWallis one-way analysis of variance. Correlation analyses were performed by calculating Spearman rank correlation coefficient (Rs). All tests were considered statistically significant at p < 0.05.
Results
Development of isoform specific qPCR assays
Primer design for GFAP-specific isoform qPCR assays was based on targeting unique sequences in the different GFAP isoforms following the same approach as described for the mouse GFAP isoforms (Kamphuis et al., 2012) . Assay specificity and sensitivity was tested on serial dilutions of plasmid templates of the different GFAP isoforms. No cross-reaction was found for the specific primers for GFAPb, GFAPg, GFAPd, GFAPk, GFAPD135, GFAPD164, GFAPDEx6, and GFAPDEx7. GFAPz-specific primers were positioned in intron 8/ 9 and exon 9 (Zelenika et al., 1995) . On human cDNA, this resulted in clear amplification in all samples, whereas no amplification was found when omitting the reverse transcription step.
GFAP isoform transcript level profile in human hippocampus
For the analysis of the qPCR data, a normalization factor based on 10 selected reference genes was used. RNA samples with a RIN value of less than 5.0 were excluded from analysis because they had a poor correlation with the normalization factor. Of the remaining samples included in the study here, the correlation between the RIN value and the normalization factor was R S ¼ 0.83; n ¼ 75; p < 0.001 [Spearman rank correlation coefficient] (Fig. 1A) , indicating that differences in RNA quality significantly contribute to the variation of assessed transcript levels, and that a proper normalization procedure is require to correct for this (Fleige and Pfaffl, 2006) . In addition, the efficiency of the qPCR assays was not affected when using cDNA samples from RNA with RIN values within the range of 5.0e8.0 (data not shown).
GFAPa, GFAPb, GFAPg, GFAPd, GFAPk, GFAPz, GFAPDEx7, and GFAPD135 transcript levels were determined in all 75 samples. GFAPDEx6 was detected in 56 of the 75 samples, and GFAPD164 in 49 of 75 samples without clear correlation with AD stage.
Using plasmid calibration curves, the relative expression of the isoforms was estimated. Setting the amount of GFAPa at 100%; transcript levels of the other isoforms were calculated as a percentage of GFAPa expression to determine a profile for each individual sample. In the amyloid O group, median values for the different isoforms were as follows: GFAPb, 0.00120% (0.0008e0.0016); GFAPd, 1.5% (1.3e1.7); GFAPk 1.1% (0.7e1.7); GFAPz, 0.21% (0.17e0.38); GFAPD135, 0.24% (0.21e0.28); GFAPD164, 0.00017% (0.00006e0.00036; n ¼ 8), GFAPDEx6, 0.009% (0.001e0.012; n ¼ 9), and GFAPDEx7, 0.006% (0.005e0.014) (n ¼ 13; median and 25the75th percentile range). Statistical analysis of the profiles revealed a significantly reduced contribution of GFAPb at Braak stages 2, 3, 4, and 5 (for each stage, p < 0.003), reaching an 8-fold reduction compared to Braak stage 0 (0.00015% vs. 0.00120%) at Braak stage 3.
None of the other isoforms showed a significant change in the relative expression profile related to either amyloid stage (O, A, B, or C), Braak stage, or age (51e96 years).
GFAP isoform transcript levels are increased in human AD
With respect to amyloid score (Table 1) , statistically significantly altered GFAP transcript levels were found for GFAPa, GFAPd, GFAPz, GFAPk, GFAPD135, and GFAPDEx7 (KruskaleWallis One-way analysis of variance on ranks; p < 0.05). Compared to amyloid O, GFAPa levels significantly increased 1.3-fold in amyloid A, 2.1-fold in amyloid B, and 2.5-fold in amyloid C samples (Fig. 1B) . A comparable pattern of elevated transcript levels with similar fold changes was found for the other isoforms, although the changes in amyloid A were not statistically significant (Table 1) . Transcript levels of genes encoding for other intermediate filament genes vimentin, nestin, synemin-a, and synemin-b were also increased along the same pattern as that of GFAP (Table 1) . In contrast, other astrocyte specific genes were decreased (glutamate transporter 1; SLC1A2 or GLT1) or not significantly changed (glutamine synthetase; GLUL) (Table 1) .
With respect to the Braak stages (Table 2) , the transcript levels for GFAPa increased in 2 phases: approximately a 2-fold elevation at Braak 1, Braak 2, and Braak 3, and a further increase to approximately 3-fold at Braak 4, Braak 5, and Braak 6 (Fig. 1C) . GFAPd, GFAPz, GFAPk, and GFAPD135 followed the same pattern. GFAPb significantly decreased in Braak stages 3 and 4, and recovered thereafter ( Table 2 ). The decreased expression levels of GFAPb, with the increase in the other isoforms at the same time, relates to the reduced contribution of GFAPb in the profile at Braak stages 2, 3, 4, and 5, as described above. GFAPDEx7 levels initially had a similar but non-significant trend for a decrease in early Braak stages, but increased at later Braak stages (Table 2) .
GFAP isoform specific antibodies
To test the isoform specificity of the different antibodies, a Western blot loaded with the 6 different recombinant GFAP isoform proteins, obtained by plasmid transfection in SW-13cl.2 cells, was stained. The GFAPpan antibody, frequently used as a marker for astrocytes, recognized all GFAP isoforms ( Fig. 2A) . The GFAPc-term antibody against the C-terminus of GFAPa did not stain GFAPDEx6 and GFAPD164 protein or GFAPd and GFAPk, only GFAPa and the inframe isoform GFAPD135 (Fig. 2B) . Staining of the Western blot with the GFAP þ1 antibody resulted in 1 band of approximately 50 kDa in the lanes containing GFAPD164 and GFAPDEx6 protein (Fig. 2C ). The GFAPD164 band was slightly higher than the GFAPDEx6 band, reflecting the 19 amino acids difference between the 2 isoforms. No bands were detected with the GFAP þ1 antibody in protein samples of GFAPa, GFAPd, GFAPk, and GFAPD135. These data are in agreement with our earlier findings (Middeldorp et al., 2009b) . The GFAPk antibody recognized only GFAPk (Fig. 2D ). The specificity of the GFAPd antibody was demonstrated previously (Roelofs et al., 2005) . For immunostainings, a GFAPmono antibody was used that recognizes GFAPa, -d, -k, and D135, but not any of the GFAP þ1 isoforms (Kamphuis et al., 2012) .
GFAP isoform immunostaining
Immunofluorescent stainings on briefly fixed cryosections results in a much improved detection of intermediate filament staining compared to paraffin-embedded sections, as we have used in earlier studies (Roelofs et al., 2005; van den Berge et al., 2010) . In cryosections, a dense network of processes immunopositive for GFAPpan, GFAPmono, or GFAPc-term was observed throughout the hippocampus of controls and AD donors at all stages. The staining intensity of this network in the subiculum was much lower. Unexpectedly, GFAPpan, GFAPmono, or GFAPc-term staining intensity was not strikingly increased in astrocytes around plaques in the hilus and CA4 region of the hippocampus (Fig. 3A) . In contrast, plaque-associated astrocytes in CA1-3 and the subiculum showed a profound increase of GFAP staining intensity compared to nonplaque areas (Fig. 3B ). In these areas and in the molecular layer of the dentate gyrus, we also detected many examples of plaques without any sign of gliosis (Figs. 3B, 4B ). In addition, reactive astrocytes were found that surrounded small areas of Ab staining with a non-filamentous pattern (Fig. 3C) .
GFAPd-stained astrocytes were found throughout the hippocampus, but in some areas GFAPd immunoreactivity was consistently more prominent. In particular, all astrocytes in the dentate gyrus subgranular zone, hilus, and CA4 area displayed intense GFAPd staining ( Fig. 3D and E) . Subgranular zone astrocytes extended long, GFAPd-positive processes into the granular layer and the molecular layer (Fig. 3E) . Few GFAPd-positive astrocytes were observed in the molecular layer ( Fig. 3D and E). Many GFAPd cells were found in the stratum lacunosum-moleculare of CA1-3 and the alveus. In the pyramidal cell layer of CA1-3 subregions and the subiculum, GFAPd staining was observed in only a few astrocytes. Double staining showed co-localization of GFAPd-positive astrocytes with GFAPc-term ( Fig. 3E and F) . In general, the GFAPd was preferentially localized in the more proximal processes of cells, resulting in a typical star-shaped pattern, whereas GFAPc-term reached into the finer branches of the processes, resulting in a more mesh-like appearance of the staining ( Fig. 3E and F) . No alteration of this GFAPd distribution pattern was noted at any of the AD stages. Plaque-associated astrocytes in the subgranular zone, hilus, and CA4 region did not show a profound increase GFAPd or GFAPc-term staining intensity (Fig. 4A) . In contrast, astrocytes near plaques in the CA1-3 or subiculum, had clearly increased expression of both GFAPc-term and GFAPd, demonstrating the classical pattern of plaque-associated gliosis (Fig. 4B) . GFAPk staining could not be detected (data not shown).
Vimentin was widely distributed over the whole hippocampus, with a distribution overlapping that of GFAPc-term and GFAPd. Intense vimentin staining was found in reactive astrocytes ( Fig. 4C and D) . Many examples of dense cored plaques were found with 1 or more strongly vimentin-positive, GFAPd-negative cells in or near the plaque with few short processes (Fig. 4D) , tentatively being activated microglia (Jiang et al., 2012) .
Nestin expression was generally not detected in astrocytes in the brain parenchyma. Few cells in subgranular zone were immunopositive and formed a network of fine processes. This staining pattern was observed in Braak 0e2 donors only (Fig. 4E) . The nestin-positive cells in subgranular zone were heterogeneous in their staining intensity for GFAPd (Fig. 4E) and vimentin (not shown). Reactive astrocytes in the hilus-CA4 region were mostly nestin positive (Fig. 4C) , whereas GFAPd-positive reactive astrocytes near plaques in the CA1-3 and subiculum were not (Fig. 4D) .
It has been documented that synemin is expressed by reactive astrocytes (Jing et al., 2007) , but its expression in AD-related gliosis has not been described. A few strongly stained cells were observed in the hippocampus, but in most cases without clear spatial relation to plaques or reactive gliosis (Fig. 4F) . GFAP þ1 staining was detected in a subpopulation of cells with a very characteristic morphology, as reported previously (Boer et al., 2010; Hol et al., 2003; Middeldorp et al., 2009b) . Table 2 Results of quantitative polymerase chain reaction assays GFAP þ1 -expressing cells were consistently found in low numbers throughout the section in both gray and white matter areas of controls without dementia as well as in AD patients, following a similar distribution pattern in all donors, although the number of GFAP þ1 -expressing cells increased with AD progression, as described in section 3.7. There was no evident association with plaques, and the morphology of GFAP þ1 cells in areas of astrogliosis was not noticeably different from GFAP þ1 cells in nongliotic areas. Most frequently, GFAP þ1 cells were found in the vicinity of the DG (Fig. 5A ), in the subventricular zone (SVZ) of the lateral ventricle (LV) adjoining the hippocampus (Fig. 5B) , and in the subpial layer of the subiculum and entorhinal cortex when these were included. GFAP þ1 -expressing cells in the subpial layer often extended long processes into deeper layers (Fig. 5C ). Some GFAP þ1 cells detected in our 10-mm hippocampal sections contained many shorter processes and a number of thin longer processes (Fig. 5D ), whereas other GFAP þ1 cells had several long processes (Fig. 5E) . In some cases, we could measure processes 0.75 mm in length without clearly detecting the termination point of these processes. Cells with these morphologies were sporadically found at different locations throughout the hippocampal area. We also observed rare GFAP þ1 cells with striking swellings in their processes, which were not clearly terminating structures, as the processes continued on both sides of the structures ( Fig. 5F ; arrows). GFAP þ1 often terminated on blood vessels, sometimes with clear endfeet (Fig. 5G ).
GFAP þ1 astrocytes are mature non-reactive astrocytes
To investigate the identity of the subpopulation of GFAPexpressing cells, various markers were double-labeled with GFAP þ1 . The soma of most GFAP þ1 cells was negative for GFAPcterm (Fig. 6A) . The processes of GFAP þ1 cells displayed intense staining intensity, whereas co-staining with GFAPc-term or GFAPmono was mostly undetectable (Fig. 6A and B) . Occasionally, a GFAP þ1 -positive cell was found that did show detectable GFAPcterm staining in the soma and the proximal processes (Fig. 6C) .
To study whether GFAP þ1 cells are astrocytes or a distinctive GFAP expressing cell type, we double-labeled for GFAP þ1 and astrocyte-specific markers S100B (Fig. 7A ) and glutamine synthetase (GS) (Fig. 7BeD ) in brain sections of subjects with different stages of AD. Most, but not all, GFAP þ1 cells co-expressed S100B in the soma and in some processes proximal to the soma (Fig. 7A,  arrow) , except in more distal processes. Many S100B-expressing astrocytes were negative for GFAP þ1 (Fig. 7A, arrowheads) indicating that GFAP þ1 is expressed only in a small fraction of all S100B-expressing astrocytes, similar to pan-GFAP and GFAPc-term. The results for GS were comparable to those for S100B, as most GFAP þ1 -expressing cells also expressed GS in the soma and proximal processes but not in the more distal parts of the processes (Fig. 7B , arrow). Many cells were found to be GS positive but GFAP þ1 negative (Fig. 7B, arrowheads) . In some instances, GFAP þ1 -labeled cells were detected that did not express GS (Fig. 7C , arrow) or S100B (not shown), whereas they were surrounded by numerous cells that expressed these proteins (Fig. 7C, arrowheads) . GFAP þ1 cells residing in the subventricular zone did not express GS (Fig. 7D , arrow), whereas astrocytes in the neighboring parenchyma did express GS (Fig. 7D, arrowheads positive cells (Fig. 8A ). Nestin expression was generally not found in astrocytes within the brain parenchyma, only in subventricular zone astrocytes and in ependymal cells aligning with the lateral ventricle. Moderate expression of nestin was detected in the GFAP þ1 cells in this area (Fig. 8B, arrows) , but intensely nestinlabeled cells were not found to express GFAP þ1 (Fig. 8B , arrowhead). Synemin was only rarely co-localized with GFAP þ1 (not shown). Again, no differences were noted in this staining pattern at the different stages of AD. Hypertrophic astrocytes were intensely stained by vimentin and GFAP, contained thicker cell processes, and appeared larger compared to nonreactive astrocytes. GFAP þ1 cells that were surrounded by reactive astrocytes clearly differed in morphology from these cells (Fig. 8C and D, arrows). They were larger in diameter due to considerably longer processes, and vimentin and GFAP expression was not apparent in these processes. Moreover, the morphology of GFAP þ1 cells in areas of astrogliosis was not noticeably different from GFAP þ1 cells in non-gliotic areas.
Number of GFAP þ1 -expressing astrocytes is closely associated with AD pathology
To investigate GFAP þ1 expression in relation to AD pathology, we quantified the number of GFAP þ1 cells in relation to AD pathology in the same sections. The total number of GFAP þ1 cells/cm 2 ranged from 4e82 and the number of GFAP þ1 cells/cm 2 significantly correlated with the amyloid staging (spearman rank correlation: R S ¼ 0.58, p < 0.001, Fig. 9A ). Amyloid O was significantly different (Fig. 9C ).
Only some GFAP þ1 -expressing cells were found in close proximity to plaques, even with processes protruding through the plaques (Fig. 9D) . Because the amyloid staging technique does not reflect the precise level of amyloid deposition in the hippocampus, the total number of amyloid plaques was quantified in the same sections used for GFAP þ1 cell counts. With an automated segregation mask, Fig. 3 . GFAP isoform stainings in hippocampus (A) A dense network of astrocytic processes is present throughout the hippocampus; illustrated here in the CA4 region by GFAPmono staining. In this area, the staining intensity and morphology of this network is hardly influenced by plaques. (B) GFAPc-term staining in stratum pyramidale of CA1 illustrating the increased GFAP expression around some (arrowhead) but not all plaques (arrows). (C) GFAPc-term staining in stratum pyramidale of CA1 showing increased GFAP staining around small fragmented Ab deposits (arrows). (D) Low magnification of the dentate region with the high density of GFAPd-positive astrocytes in the subgranular zone, hilus, and CA4. Note the near absence of GFAPd-staining in the stratum moleculare. (E and E') Double staining of GFAPd and GFAPc-term in the dentate gyrus. Processes extending into the granular cell layer and the molecular layer are more GFAPc-term positive (arrowheads), whereas the cell bodies in the SGZ are more intensely stained for GFAPd (arrows), but the ratio differs between cells (long arrow vs short arrow). (F and F') High magnification of a typical GFAPd-positive cell in the hilus double stained with GFAPc-term. Proximal processes are doublepositive (arrows), whereas the finer GFAPc-term processes are not detectable by GFAPd-staining (arrowheads) . ( expressing astrocytes were detected with striking thickenings in its processes (F, arrows). Frequently GFAP þ1 astrocyte processes (red) were found in contact with a blood vessel (asterisk), labeled here by vimentin (green). The process terminating on a blood vessel often presented a clear endfeet structure, which is more clear at higher magnification (G, boxed area). NBB 01-103, female 93 years, Braak 3, amyloid B (AeG).
mean AE SEM) and females (32.4 AE 0.2 GFAP þ1 cells/cm 2 ; p ¼ 0.007). This difference is, to some extent, caused by the fact that the average age of the female donors (82 AE 2 years) was higher compared to that of males (76 AE 2 years, p < 0.007). Plaque number density and plaque coverage was not different between females and males. (Fig. 9F) .
GFAP þ1 expression in astrocytes is induced by Ab1-42 in vitro
In view of the increased number of GFAP þ1 -expressing cells in the course of AD, we tested whether Ab could induce the expression of this splice variant in U343 astrocytoma cells that normally do not express GFAP showed a decrease of greater than 30%, and after 3 days formazan formation was less than 50% compared to that in controls. However, for both oligomers and fibrils, the decrease was stabilized after 3 days (Fig. 10A) . Microscopic inspection of the treated cell cultures did not show obvious cell death or clear morphological changes (not shown).
Immunostaining for GFAP þ1 expression in the Ab-treated cultures revealed a small number of GFAP þ1 -expressing cells after treatment with 1 mmol/L Ab fibrils for 1 day (Fig. 10B ). More frequent and larger clusters of GFAP þ1 -expressing cells were found after 3 days of Ab fibril treatment in 2 of 4 experiments (Fig. 10C) . Also after 7 days of Ab fibril treatment several GFAP þ1 -expressing cells were detected in 1 experiment (Fig. 10D) . After 1 day of Ab oligomer treatment, no GFAP þ1 -positive cells were observed; however, after 3 days exposure to Ab oligomers, several GFAP þ1 -expressing cells were found in 1 experiment (Fig. 10E) , and even more after 7 days of Ab oligomer treatment in all 3 experiments (Fig. 10F) . In 1 experiment, a few GFAP þ1 -expressing cells were also found after 3 and 7 days in the control condition without the presence of Ab in the culture (Fig. 10G) . In addition to GFAP þ1 , we also stained for Ab, which showed some small green spots in the oligomer-treated cultures (Fig. 10E, arrowheads) and large aggregates in the fibril-treated cultures (Fig. 10D,  arrowheads) . Fig. 7 . Double-labeling of GFAP þ1 with S100B and glutamine synthetase S100B (A and A') and glutamine synthetase (B and B') are expressed in many astrocytes (arrowheads) colocalize with GFAP þ1 -positive cells (arrow); however, also GFAP þ1 astrocytes (arrows) also are found that do not co-localize with glutamine synthetase (C and D) while being surrounded with glutamine synthetaseeexpressing astrocytes (arrowheads), both in the hippocampus (C) and in the subventricular zone (D). (A and B) NBB 00-107, male 70 years, Braak 5, amyloid C; (B) NBB 01-094, male 86 years, Braak 2, amyloid B.
GFAP þ1 isoforms in vitro
GFAPk or GFAP þ1 isoforms were overexpressed in SW-13cl.2 adrenal carcinoma cells by plasmid transfection ( Supplementary  Fig. 1 ). Overexpression of GFAPd was reported previously, and revealed that GFAPd alone is unable to form an IF network, and coexpression with GFAPa results in a collapse of the existing network (Roelofs et al., 2005) . SW-13cl.2 cells lack endogenous expression of cytoplasmic IF proteins, which enabled us to study whether GFAP þ1 proteins could homodimerize and form filaments by itself.
Transfection of only GFAPa in SW-13cl.2 cells revealed a clear IF network throughout the cell when stained for GFAPc-term ( Supplementary Fig. 1A ), indicating self-assembly of GFAPa. GFAP þ1 staining of cells transfected with GFAPD164 ( Supplementary Fig. 1B ), GFAPDEx6 ( Supplementary Fig. 1C ), or GFAPk ( Supplementary Fig. 1K ) showed that these isoforms are not capable of forming filaments by themselves. Co-transfections of GFAPa and GFAPk or GFAP þ1 isoforms did not yield filaments when cells were transfected with 25%e50% GFAPa ( Supplementary  Fig. 1E, F, H, I , L, and M). Only in a number of cells that were transfected with 90% GFAPa and 10% GFAP þ1 ( Supplementary   Fig. 1G and J) or with 25% GFAPk (Supplementary Fig. 1M ) small filamentous structures were formed, but not as extensive as with 100% GFAPa (Supplementary Fig. 1A ).
In addition, transfection of GFAP isoforms in U343 astrocytoma cells that endogenously express GFAPa but not GFAPD164 or GFAPDEx6, was performed to analyze possible heterodimer formation and the effect of induced GFAP þ1 expression on the morphology of these cells with a pre-existing IF network ( Supplementary Fig. 2 ). Transfection with GFAP þ1 isoforms ( Supplementary Fig. 2AeD ) resulted in an improved filament formation compared to SW-13cl.2 cells, but was still compromised compared to untransfected U343 cells.
Discussion
The aim of this study was to characterize the expression pattern of different GFAP isoforms in normal human hippocampal tissue and in conditions with AD-related gliosis using an approach comparable to that in our previous work in wild-type and AD mice (Kamphuis et al., 2012) . To this end, we have developed isoform specific qPCR assays and used our unique collection of antibodies against human GFAPd, GFAP þ1 , and GFAPk. The main novel findings are as follows: (1) The quantification of relative expression levels of the different GFAP isoform encoding transcripts in both control and AD subjects shows that 7 different isoforms are expressed in all samples; (2) novel isoforms GFAPDEx7 and GFAPz at the transcript level in human brains were identified; (3) transcript levels of all GFAP isoforms increase in concert with AD progression except for GFAPD164 and GFAPDEx6; (4) GFAPd immunostainings show a widespread distribution in human hippocampus, with a high expression in the SGZ and CA4 region and an increased expression in reactive astrocytes near plaques; (5) GFAPk antibodies do not yield staining patterns; (6) immunostainings for frame-shifted GFAP þ1 reveal a subpopulation of astrocytes with a characteristic morphology not limited to AD cases; (7) the number of these GFAP þ1 cells increases in the course of AD, whereas the cells could not be typified as reactive astrocytes associated with plaques; and 
GFAP isoform transcript levels in human hippocampus
In human hippocampal cDNA samples, GFAPa is the most abundant isoform followed by GFAPd (1.4%), GFAPk (1.2%), GFAPz (0.2%), GFAPD135 (0.2%), with other isoforms GFAPb, GFAPg, GFAPDEx6, GFAPD164, and GFAPDEx7 all at <0.01%. This profile is based on plasmid calibration curves, which does not correct for potential different efficiencies in cDNA synthesis from the transcripts encoding for the various isoforms. However, the mixture of oligodT and random primers used, together with a slightly elevated incubation temperature of 42 C, are the optimal conditions for an efficient conversion into cDNA. Based on our previous work. (Kamphuis et al., 2012) , we now can conclude that the GFAP isoform expression -expressing cells were observed. Ab1-42 fibrils (green) form large aggregates in vitro (D, arrowheads). After 3 days (E) and 7 days (F) of exposure to Ab1-42 oligomers, several GFAP þ1 -expressing cells were observed, but also after 3 days of control treatment (G). Ab1-42 oligomers could sometimes be visualized by an Ab antibody as small spots (green) in the cell culture (E, arrowheads). Inset in f shows the fibrillary character of the GFAP þ1 staining.
profiles for mice and for human beings are rather similar, except that GFAPa in human hippocampus is even more prevalent.
GFAP isoform transcript levels increase in human AD
In human cDNA samples from AD donors all GFAP isoforms were significantly increased, reaching a 1.5-to 3.2-fold increase at endstage AD (amyloid C/Braak 6). The gradual increase of GFAPa transcript levels paralleled the progression of AD reflected by the number of plaques, amyloid scores, and Braak stages. In the APPswePS1dE9 transgenic mouse model, we described a similar increase in transcript level of all detected GFAP isoforms (Kamphuis et al., 2012) . The GFAP þ1 -encoding transcripts (GFAPD164, GFAPDEx6, GFAPDEx7) showed a general trend to increase, which may be coupled to the increased number of GFAP þ1 cells in AD. However, the assessed levels of these isoforms are very low, quite variable, and not detectable in all samples, and we do not know with certainty whether these transcripts originate only from GFAPþ1 cells or whether they are expressed by all astrocytes at very low abundance.
Astrocytes in AD hippocampus express several different GFAP isoform
From our panel of GFAP antibodies, GFAPpan, GFAPmono, GFAPd, and GFAP þ1 displayed immunostaining in sections. The staining of GFAP þ1 in a subpopulation of astrocytes with a distinct morphology is different from the mouse brain where we have been unable to detect GFAP þ1 immunostaining in either wild-type or AD mice (Kamphuis et al., 2012) . The GFAPc-term antibody is specific for the GFAPa C-terminal sequence, and we assume that the obtained immunostaining pattern predominantly reflects the expression of GFAPa in astrocytes and the increased GFAPa protein levels in reactive astrocytes around some plaques. Previously, we reported that, in the human brain, GFAPd is differentially expressed in proliferating cells in the subventricular zone (Condorelli et al., 1999a; Roelofs et al., 2005; van den Berge et al., 2010) . In the mouse brain, the distribution of GFAPd was not restricted to the subventricular zone (Kamphuis et al., 2012) . In our experience, the optimal sensitivity for IF immunostaining is obtained by using lightly fixed cryosections of frozen tissue. Following this method, we now demonstrate a clear GFAPd staining in hippocampal astrocytes with a preferential localization in the proximal processes. Astrocytes in the SVZ, SGZ, and CA4 region of the hippocampus displayed strong immunostaining for GFAPd. The overlap with nestin and GFAPd was only partial, and we conclude that, in contrast to the SVZ (Roelofs et al., 2005; van den Berge et al., 2010) , GFAPd is not a specific stem cell marker in the SGZ. In line with the increases in GFAPd transcript levels, GFAPd immunostaining was increased in reactive astrocytes around plaques.
GFAPk transcript was clearly detectable in all samples and levels increased in AD tissue, but the predicted protein could not be detected which is in line with our observations in mouse brain model (Kamphuis et al., 2012) .
Our observations are in good agreement with the outcome of studies demonstrating that GFAP expression levels are highly associated with plaque load (Hanzel et al., 1999; Muramori et al., 1998; Vehmas et al., 2003) . Exposure of astrocytes in culture to different forms of Ab resulted in GFAP upregulation and various other astroglial alterations such as the production of inhibitory extracellular matrix proteins and a change of morphology without compromising viability (Datki et al., 2004; Hu et al., 1998; Nielsen et al., 2009; Salinero et al., 1997) . Astrocytes are able to actively remove Ab through uptake, which may reduce the amyloid deposition in the brain (Allaman et al., 2010; Apelt et al., 2003; Nielsen et al., 2009; Pihlaja et al., 2008 Pihlaja et al., , 2011 Thal et al., 2000b; Wisniewski and Wegiel, 1991; Wyss-Coray et al., 2003) . As it has become clear that the absence of GFAP alters the response of astrocytes in a profound manner, it may be hypothesized that the increase in GFAP in reactive astrocytes influences plaque load. In fact, in a recent study by Kraft et al., it was shown that GFAP À/À vimentin À/À eAPPswePS1dE9 mice have an increased plaque load and more dystrophic neurites around plaques, signifying a neuroprotective function of the IF network in astrocytes (Kraft et al., 2012; Otani et al., 2006) . GFAP À/À astrocytes fail to form a barrierlike structure around Ab deposits (Xu et al., 1999) and have impaired cell motility (Lepekhin et al., 2001 ). These observations support an involvement of astrocytes and the IF network of astrocytes in the process of reactive gliosis as it occurs in AD. The results of the transfection studies on SW-13cl.2 cells, lacking endogenous expression of intermediate filament proteins, and on U343 cells provided evidence that only GFAPa is able to form a network of fine filaments throughout the cell, whereas transfection with GFAPd (Roelofs et al., 2005) , GFAPk (Blechingberg et al., 2007) , and GFAP þ1 isoforms (the current paper) results in a compromised network. The detrimental effects of GFAPd or GFAP þ1 on the network could be partly counteracted by a co-transfection of GFAPa or when cells with a pre-existing IF network were transfected. Given the profile of GFAP isoform transcript levels as determined in human samples, it seems unlikely that, in vivo, the GFAP network is compromised by high levels of GFAPd, as we did not observe GFAPd staining aggregates in cells.
GFAP þ1 is expressed by morphologically distinct subpopulation of astrocytes
In contrast to the mouse brain, we observed GFAP þ1 -positive cells in the human hippocampus, subiculum, entorhinal cortex, caudate/putamen, spinal cord, and SVZ (Middeldorp et al., 2009b mm and 400 mm, with an average of 143 mm, and the longest processes exhibit an average length of 98 mm (Oberheim et al., 2009 ).
Although some GFAP þ1 -expressing cells fit these measurements, many GFAP þ1 cells had much longer processes, even up to 1 mm in length. The morphology of the GFAP þ1 -positive cells matches with the morphology of varicose projection astrocytes in layers 5 and 6 of the human cortex (Oberheim et al., 2009) . These cells were shown to extend 1e5 long processes up to 1 mm in length terminating in the neuropil or on the vasculature. Comparable to processes of GFAP þ1 astrocytes, varicose projection astrocytes often contacted brain capillaries. A noticeable difference is the lack of regularly spaced varicosities present on the processes of GFAP þ1 cells (Oberheim et al., 2009) . The interlaminar astrocytes shown by Oberheim et al. resemble some of the subpial GFAP þ1 astrocytes that we found in our study (Fig. 5C) . Some of the morphological differences between our study and the Oberheim study could be explained by a difference in brain area (hippocampus vs. transcripts, but a consistent profile did not emerge (not shown). It must also be noted that our constructs express the N-terminus of GFAPa; however, the exact sequence of the N-terminal head domain of GFAPD164 and GFAPDEx6 transcripts in vivo has not yet been determined. Therefore, these constructs may not represent the endogenous expressed GFAP þ1 isoforms, and thus the IF formation capacity might differ from the results we obtained with our expression constructs.
Number of GFAP þ1 cells is increased in AD
Whereas it is unlikely that GFAP þ1 cells are reactive astrocytes,
we did find that the number of these GFAP þ1 -expressing astrocytes significantly increases during the progress of AD with lesser effects of gender and age. The in vitro studies showed that treatment with Ab 1e42 oligomers and fibrils increases the number of GFAP þ1 -positive cells, suggesting that elevated Ab level is a causative factor. However, also in control culture, some GFAP þ1 induction was noted.
GFAP þ1 -expressing cells in vitro always manifested as clusters, which might indicate that, at least in vitro, not splicing but rather a somatic mutation leading to a permanent transition of the frameshifted reading frame in 1 of the GFAP gene copies underlies the GFAP þ1 in some cells. In 75%e85% of mouse cortical astrocytes, only 1 of the 2 GFAP loci in the genome is active, whereas the other is rendered non-functional (Takizawa et al., 2008) . A genetic modification changing the reading frame of the active locus into GFAP þ1 would also result in the complete loss of the GFAPa isoform, which is in line with the observation that the majority of GFAP þ1 cells does not express detectable GFAPa. The gradual accumulation of such mutations over the years could explain the slow rise in number with age, and, in a previous study, we did not observe GFAP þ1 cells in young adults (<50 years old) and during development (Boer et al., 2010; Middeldorp et al., 2009b) . Despite a high spontaneous DNA damage rate, irreversible DNA mutations occur only at a very low frequency due to different repair systems. However, aging may lead to an increased rate of DNA damage, whereas DNA damage repair functions may become compromised and more error prone (Li and Vijg, 2012) . Using a mouse reporter model, an agerelated increase in mutation frequency in several tissues including the brain was found. The brain showed a particularly low mutation frequency, but in the hippocampus this significantly increased 2-fold between 7 months and 30 months of age (Busuttil et al., 2007) . Finally, several mechanisms regulate promoter activity of the GFAP gene: DNA methylation, histone methylation and acetylation, and spatial positioning (Bai et al., 2013; Kanski et al., in press) . A stable epigenetic alteration creating a dominance of a usually rare isoform at the expense of GFAPa may also underlie the existence of GFAP þ1 cells (Luco et al., 2011) . Whether the increase in number of GFAP þ1 cells in AD has any consequences for the disease process cannot be derived from the data collected.
In conclusion, this study shows that at the transcript level the canonical GFAPa isoform is accompanied by low levels of all other known isoforms, and that, in AD, all transcript levels increase, maintaining stable relative isoform RNA levels. Previously we described GFAPd-isoform to be highly expressed in neurogenic astrocytes in the human subventricular zone (Roelofs et al., 2005; van den Berge et al., 2010) . However, we here conclude that GFAPd is not an exclusive marker for these cells, because GFAPdstained astrocytes were found throughout the hippocampus as well as in reactive astrocytes. GFAP þ1 is expressed in a subpopulation of nonreactive astrocytes in elderly controls without dementia and in subjects with AD. This relatively low number of GFAP þ1 -expressing cells cannot be categorized within 1 of the known astrocyte subtypes. From the results presented in this study, we suggest that a mutation underlies the formation of new GFAP þ1 cells out from astrocytes, and that the frequency of this rare event is increased by Ab-related cellular stress. Future exploration of underlying mechanisms concerning the function of GFAP þ1 proteins is needed to elucidate the role of a specialized IF network in astrocytes in health and disease.
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